Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.
With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.
Dr. Watterson Has Identified a Number of New Classes of Central Nervous System Drugs
The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias.
With Better Evidence, Routine Medical Decisions Could Help Prevent Dementia
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have jointly committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade. And it has the potential to advance treatments for other neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s.
The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression. The grants include funding for four novel programs with the potential to treat a range of diseases, including Alzheimer’s, Huntington’s, and Parkinson’s.
Annual Gala Raised over $3.25 million for Alzheimer’s Treatments
Sixth Annual Great Ladies Luncheon & Fashion Show most successful in event's history